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Natural killer cells are increasingly being considered an important component of innate resistance to viruses, but their role in
HIV infection is controversial. Some investigators have found that natural killer cells do not confer a protective effect during the
progression of HIV disease, whereas others have shown that natural killer cells may be protective and retard the progression of the
disease, either through their lytic activity or by a chemokine–related suppression of HIV replication. In this study, we analyzed
functional alterations in the activity of natural killer cells during HIV-1 infection using a natural killer cells activity assay with K562
cells as targets.
Results: Our results show that the activity of natural killer cells decreases only in the advanced phase of HIV infection and
when high (40:1) effector cell-target cell ratios were used. The depression at this stage of the disease may be related to increased
levels of some viral factors, such as gp120 or gag, that interfere with the binding capacity of natural killer cells, or to the decreased
production of natural killer cells -activity-stimulating cytokines, such as IFN-a and IL-12, by monocytes, a subset of cells that are
also affected in the late stage of HIV infection. The data suggest that decreased natural killer cells cell activity may contribute to the
severe impairment of the immune system of patients in the late stages of HIV infection.
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Natural killer cells (NK) are active
in the earliest stages of the host defense
and have been increasingly recognized
as an important component of innate
resistance. In fact, NK cells display
broad specificity, rapid activation, and
play a role in cell-mediated cytotoxic-
ity and lymphokine production. In con-
trast to B and T lymphocytes, which
are involved in specific (acquired) im-
munity, NK cells possess an apparently
innate ability to respond to tumor cells
and cells infected by intracellular
pathogens, such as viruses1.
There have been controversial re-
ports on the role of the NK cells in the
pathogenesis of HIV infection. While
some investigators have found that NK
cells do not confer a protective effect
against the progression of HIV dis-
ease2,3, others have shown that NK cells
may play a protective role in HIV in-
fection4, 5.
HIV infection is a public health
concern in Brazil and occurs mainly in
highly populated areas, such as the
State of São Paulo, which has been re-
sponsible for half of the cases reported
in the last 20 years6. A cohort has been
followed since 1985 to study HIV dis-
ease progression in São Paulo7. In the
present study, we report preliminary
results on the functional analyses of
NK cells activity during HIV-1 infec-
tion in this cohort.
PATIENTS AND METHODS
Forty-one HIV-1-infected patients
(30 males and 11 females) were evalu-
ated. The mean (±SD) age of patients
was 33 ± 7 years old. Twenty-two were
homosexual or bisexual men, 14 indi-
viduals were heterosexuals, 4 were in-
travenous drug users, and for one case
the infection route was unknown. All
participants gave written informed con-
sent for the present study. The subjects
were classified according to the T
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CD4+ cell count criteria8: Group I, >
500 cell/mm3; Group II, 200-500 cells/
mm3; and Group III, < 200 cells/mm3.
The patients were arranged in
groups according to their T CD4+ cell
counts. The mean (±SE) CD4+ T cell
counts for the three groups were as fol-
lows: for Group I (n=11), 724 ± 156;
for Group II (n=14), 373 ± 87; and for
Group III (n=16), 80 ± 55 cells/mm3.
Fifteen healthy volunteers from the
laboratory staff were evaluated as the
control group (T CD4+ count: 829 ±
346 cells/mm3).
NK cell activity was determined as
previously described2. Briefly, mono-
nuclear cells (PBMC) were separated
from heparinized peripheral blood and
resuspended to 2–4 x 106 cells/mL
supplemented with 20% fetal calf
serum (FCS) (Laborclin, Campinas,
Brazil). K562 cells were labeled with
51Cr (sodium chromate, CNEN, SP,
Brazil) and used as targets. The
patients’ mononuclear cells and 51Cr-
labeled K562 cells (1 x 105 cells/well)
were added in triplicate to microplates
with U-bottom wells (Corning Plastics,
NY, USA) at the ratios of 40:1, 20:1,
10:1, and 5:1 effector cells to target
cells5. The plates were centrifuged at
800 rpm and incubated for 4h at 37°C
in 5% CO2. The radioactivity released
to the supernatants in each well was
counted with a gamma counter
(Packard Instrument CO., Downers
Grove, IL, USA). The spontaneous
release was determined from target
cells incubated with medium only, and
the total release was measured by
incubation of the cells in 1% Triton X-
100 in PBS. The percentage of specific
lysis by the patient specimen was
calculated as an arithmetic mean as
follows: (mean cpm experimental -
mean cpm spontaneous release) / (
mean cpm total release - mean cpm
spontaneous release) x 100. The
statistical analysis was performed by
using paired t-tests to compare the NK
activity in the groups.
RESULTS
The results from these experiments
show that only patients with advanced
HIV disease (Group III), where T
CD4+ counts were below 200 cells/
mm3, showed decreased NK cell activ-
ity (45 ± 22) compared to healthy con-
trol individuals (66 ± 18) in the 40:1
effector cells/target cells ratio group
(p<0.05). We did not observe statisti-
cal differences between the other
groups using paired t-tests to compare
the groups. The results are summarized
in figure 1.
For lymphocyte proliferation as-
says, PBMCs (2 x 105 cell/well) were
cultivated in triplicate in microplates
(Costar, Cambridge, MA, USA) at
37°C with 5% CO2 in the presence of
medium only or with 5 mg/mL of phy-
tohemagglutinin (PHA). The cells were
incubated for 3 days and pulsed for an
additional 18 h with 0.5 mCi/well [3H]
thymidine (2mCi/mM, Radiochemical
Center, Amersham, UK) before being
harvested. The cell-bound radioactivity
was measured in a beta scintillation
counter (Beckman, Palo Alto, CA,
USA). The mean counts per minute of
triplicate wells were calculated and the
results were expressed as the difference
between the counts per minute of
stimulated and non-stimulated cultures.
A decreasing lymphocyte proliferation
response was observed with the pro-
gression of the disease, as has been
previously reported7. Patients in Group
I showed a mean ±SD of 20,259 ±
3,028 DCPM; patients in Group II,
13,615 ± 2,739; and patients in Group
III, 7,649 ± 1,813. Lymphocytes from
the control group proliferated signifi-
cantly more than in groups with the
HIV patients (CPM = 34,067 ± 4,420,
p<0.05).
DISCUSSION
Our results show that NK cell ac-
tivity decreased only in the advanced
phases of HIV infection and when a
high effector cell to target cell ratio
Figure 1 - Natural killer activity in HIV-1-infected patients.
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(40:1) was used. A decrease has been
reported in NK activity by nearly 75%
in HIV-1-infected patients with less
than 400 cells/mm3 compared to
uninfected individuals3. Accordingly,
we observed a marked depressed cel-
lular immunity, as assessed by de-
creased T-cell lymphocyte prolifera-
tion, in HIV-1 infected patients with T
CD4+ counts below 500 cells/mm3,7,10.
Other investigators have observed de-
pression in NK cells from the begin-
ning of the HIV infection, when cellu-
lar immunity depression was less evi-
dent5. In contrast, Ullum et al. did not
observe any difference in NK cells ac-
tivity throughout HIV-1 infection, al-
though the interferon-g induced NK
activity was depressed in GIV patients
compared to GII and GIII patients4.
The mechanism of reduced NK cell
activity in HIV-1-infected patients is still
unknown. One possibility is that it may
result from low levels of some
cytokines, such as IFN-g, which is an
important activator of NK cells and the
production of which is only affected in
the late phases of HIV disease4. The
progressive decrease in the levels of
other cytokines that are also important
regulators of NK cell activity (such as
IL-2, IL-12, and IL-15) during HIV in-
fection may also contribute to the loss
of NK cell activity. In fact, several stud-
ies have documented at least partial re-
covery of this in vitro activity through
the addition of these cytokines9,10,11.
Moreover, monocytes are only signifi-
cantly affected in late phases of HIV in-
fection, and they may be a consistent
source of IL-12 and IL-1511.
Alternatively, it has been shown
that serum from AIDS patients has a
dose-dependent inhibitory effect on
normal NK cells. Most of this inhibi-
tion is caused by immunoglobulin G,
but other factors, such as gp120, may
also contribute to this effect12. More
recently, it has been shown that NK
cells have the capacity to secrete CC-
chemokines in vivo, and therefore, sup-
press HIV replication by CC-
chemokine-mediated mechanisms in
addition to the classic NK-mediated
lytic mechanisms13. Viral products,
such as gp120 and gag, whose levels
are usually increased in the late phases
of the infection, may interfere with NK
activity, probably through the inhibi-
tion of the target binding capacity of
the effector cells14.
In the light of the increasing evi-
dence of an important role for NK cells
during HIV infection, we suggest that
decreased NK cell activity may be part
of the severe impairment of the im-
mune system observed in the advanced
phase of the disease; however, further
longitudinal studies will be necessary
to investigate whether combined
antiretroviral therapy could change NK
activity.
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As células “natural killer” são con-
sideradas importante componente da
resistência inata às viroses, mas seu
papel na infecção pelo HIV é contro-
verso. Alguns investigadores verifica-
ram que as células “natural killer” não
possuíam qualquer efeito protetor du-
rante a progressão para doença, en-
quanto outros têm mostrado que as
mesmas podem ser protetoras e retar-
dar a progressão para doença, tanto de-
vido à sua ação lítica como pela su-
pressão por quimocinas. Em nosso es-
tudo, analisamos as alterações funcio-
nais na atividade durante infecção pelo
HIV-1 usando ensaio com células
K562 como alvo. Os resultados mos-
traram que a atividade “natural killer”
está diminuída somente nas fases mais
avançadas da doença e somente quan-
do foi utilizar um número elevado de
(40:1) células efetoras-alvos. A dimi-
nuição da atividade neste estágio da
doença pode estar relacionada com a
imunossupressão grave; a presença de
alguns fatores virais, como a gp120 e
gag, que interferem como a capacida-
de de ligação das células “natural
killer”; ou a redução da produção de
citocinas que estimulam a atividade
“natural killer”, como IFN-a e IL-12,
por monócitos, uma subpopulação de
células que são afetadas somente nos
estágios mais avançados da infecção
HIV. Assim, fica sugerido que a dimi-
nuição da atividade “natural killer”
pode contribuir para alterações no sis-
tema imune de pacientes nas fases
avançadas da infecção HIV.
DESCRITORES: Infecção pelo
HIV. Células “natural killer”.
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